ConductScience.org, home

Paper42809697PubMed

CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma.

Sperling AS. Cancer J, 2026.

Cite this record

ConductScience Library. CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma. Papers, record 42809697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42809697

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma.
Journal
Cancer J
Year
2026
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural
Revised in PubMed
2026-10-06

Source PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sperling ASAdam Shttps://orcid.org/0000-0002-9369-4413

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Immunotherapy, AdoptiveMajor topic
Receptors, Chimeric AntigenMajor topic
T-LymphocytesMajor topic
Humans
Remission Induction
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA124435NCI NIH HHSUnited StatesP30CA124435PubMedNIH RePORTER
R01 DK141535NIDDK NIH HHSUnited StatesR01DK141535PubMedNIH RePORTER

Download CSV of grants

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141285709TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.Nat Commun2025https://conductscience.org/library/papers/41285709PubMed
230102295Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.Nat Biotechnol2018https://conductscience.org/library/papers/30102295PubMed
333626253Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med2021https://conductscience.org/library/papers/33626253PubMed
437486599Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy.Blood Adv2023https://conductscience.org/library/papers/37486599PubMed
540198886Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.Blood2025https://conductscience.org/library/papers/40198886PubMed
615731182Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.Blood2005https://conductscience.org/library/papers/15731182PubMed
741968163Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.Blood Cancer J2026https://conductscience.org/library/papers/41968163PubMed
828954221Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.Cell Rep2017https://conductscience.org/library/papers/28954221PubMed
929061640Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.Clin Cancer Res2018https://conductscience.org/library/papers/29061640PubMed
1041540108Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.Nat Med2026https://conductscience.org/library/papers/41540108PubMed
1134175021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
1238977912A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.Nat Med2024https://conductscience.org/library/papers/38977912PubMed
1337653344Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.Nat Med2023https://conductscience.org/library/papers/37653344PubMed
1441825801Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy.Transplant Cell Ther2026https://conductscience.org/library/papers/41825801PubMed
1537525244The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.J Hematol Oncol2023https://conductscience.org/library/papers/37525244PubMed
1641411617Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.Blood Cancer Discov2026https://conductscience.org/library/papers/41411617PubMed
1736906275Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.Transplant Cell Ther2023https://conductscience.org/library/papers/36906275PubMed
1841519141Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol2026https://conductscience.org/library/papers/41519141PubMed
1933846552CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma.Gene Ther2021https://conductscience.org/library/papers/33846552PubMed
2035468618Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.Blood Adv2023https://conductscience.org/library/papers/35468618PubMed

See all 72 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TNFRSF17608PubTator's text mininghttps://conductscience.org/library/genes/608

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42809697

GET https://conductscience.org/api/papers/v1/42809697/references?page=2